Clinical trial
Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly…
NCT00003694 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003694 |
|---|---|
| Title | Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase |
| Official title | A Phase II Study of Newly Diagnosed Patients With BCR/ABL (+) Chronic Myelogenous Leukemia Treated With Combined Homoharringtonine (NSC #141633) and Low-Dose Cytarabine |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia |
| Intervention type | Drug, Other |
| Interventions | omacetaxine mepesuccinate, cytarabine, laboratory biomarker analysis |
| Enrollment | 60 |
| Start date | Mar 1, 1999 |
| Primary completion | Aug 1, 2003 |
| First posted | Dec 5, 2003 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: